© Reuters. FILE PHOTO: Monsanto Co’s Roundup is proven on the market in Encinitas, California, U.S., June 26, 2017. REUTERS/Mike Blake/File Photograph

By Tom Hals

(Reuters) -A federal appeals court docket on Friday upheld a $25 million judgment and trial verdict discovering Bayer (OTC:)’s Roundup brought on a California resident’s non-Hodgkin lymphoma, dealing a blow to the chemical firm’s hopes of limiting its authorized threat over the weed-killer.

The trial decide didn’t misapply the regulation when he allowed the lawsuit by Edwin Hardeman to go to trial, as Bayer has argued, in accordance with a three-judge panel of the ninth U.S. Circuit Courtroom of Appeals in San Francisco.

A jury in 2019 awarded Hardeman $5 million in compensatory damages and $75 million in punitive damages. The punitive award was later reduce to $20 million, and the appeals court docket additionally upheld the discount.

The Hardeman case was the primary so-called bellwether trial for federal instances alleging Roundup causes most cancers.

Bayer has stated that many years of research have proven Roundup and different glyphosate-based herbicides that dominate the market are protected for human use.

Bayer has dedicated $9.6 billion to settle 125,000 claims over Roundup and subsequent week will search preliminary approval for a $2 billion proposed deal to resolve future claims by shoppers who’ve been uncovered to Roundup however haven’t but gotten sick.

Disclaimer: Fusion Media want to remind you that the info contained on this web site just isn’t essentially real-time nor correct. All CFDs (shares, indexes, futures) and Foreign exchange costs will not be offered by exchanges however slightly by market makers, and so costs will not be correct and will differ from the precise market worth, which means costs are indicative and never acceptable for buying and selling functions. Due to this fact Fusion Media doesn`t bear any accountability for any buying and selling losses you would possibly incur because of utilizing this information.

Fusion Media or anybody concerned with Fusion Media won’t settle for any legal responsibility for loss or injury because of reliance on the knowledge together with information, quotes, charts and purchase/promote alerts contained inside this web site. Please be absolutely knowledgeable relating to the dangers and prices related to buying and selling the monetary markets, it is without doubt one of the riskiest funding types attainable.